Aligos Therapeutics (NASDAQ:ALGS) Raised to “Strong-Buy” at Cantor Fitzgerald

Aligos Therapeutics (NASDAQ:ALGS) was upgraded by Cantor Fitzgerald to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

Several other analysts have also commented on the company. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Monday, April 20th. Jefferies Financial Group raised shares of Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. Westpark Capital assumed coverage on shares of Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, May 17th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $37.20.

Aligos Therapeutics Stock Performance

Shares of Aligos Therapeutics stock opened at $5.71 on Thursday. The firm has a 50-day simple moving average of $6.91 and a two-hundred day simple moving average of $7.92. Aligos Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $13.69. The company has a market cap of $35.34 million, a P/E ratio of -0.66 and a beta of 2.28.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, May 7th. The company reported ($2.21) EPS for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The firm had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. Equities research analysts forecast that Aligos Therapeutics will post -7.54 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP purchased a new position in Aligos Therapeutics in the 1st quarter valued at $2,602,000. Marshall Wace LLP purchased a new stake in shares of Aligos Therapeutics during the fourth quarter worth $2,504,000. Bank of America Corp DE raised its position in shares of Aligos Therapeutics by 1,652.8% in the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after buying an additional 216,646 shares during the last quarter. Readystate Asset Management LP lifted its stake in Aligos Therapeutics by 48.5% in the 3rd quarter. Readystate Asset Management LP now owns 203,113 shares of the company’s stock worth $1,991,000 after purchasing an additional 66,331 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Aligos Therapeutics by 22.8% during the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after buying an additional 31,913 shares in the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.